Clinical Trials

Multiple clinical trials evaluate the diagnostic utility of iothalamate sodium clearance for measuring glomerular filtration rates and renal functional reserve in conditions including kidney donation, kidney failure, renal transplantation, chronic kidney disease, and liver failure with renal impairment. Sponsored by academic institutions, medical centers, and government bodies such as the National Institute of Allergy and Infectious Diseases, Stanford University, and Brigham and Women's Hospital, these studies encompass both completed trials and those with unknown recruitment status. Across this portfolio, trial phases are designated as either unprovided or not applicable.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06259422 UNKNOWN
Kidney Function Issue; Diagnosis; Chronic Kidney Diseases
University Medical Center Groningen
2024-06-01
NCT03190070 COMPLETED
Kidney Diseases
Brigham and Women's Hospital
2017-07-12

(data from https://clinicaltrials.gov, updated on 2024-03-13)

Check the iothalamate sodium product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Iothalamate sodium contains a tri-iodinated benzene ring that absorbs X-ray radiation to enhance radiocontrast, while remaining biologically inert without inhibiting specific cellular biochemical cascades. Following systemic administration, the compound undergoes renal elimination via passive glomerular filtration without tubular secretion or reabsorption, making its clearance rate a precise indicator of glomerular filtration rate for diagnostic evaluation in clinical settings such as kidney diseases, renal failure, and liver failure.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.